An2 Therapeutics, Inc. ANTX
Institutional shares held
7.58 Million
0
calls
0
puts
Total value of holdings
$8.04M
$0
calls
$0
puts
Market Cap
$20.6M
19,402,700
Shares Out.
Institutional ownership
39.08%
# of Institutions
38
We take great care to ensure that the data presented and summarized in this overview for AN2 Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANTX
View all-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.51 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.1 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$617,7360.62% of portfolio
-
Stonepine Capital Management, LLC Bend, OR544KShares$577,1630.57% of portfolio
-
Landscape Capital Management, L.L.C.495KShares$525,1190.05% of portfolio
-
Bank Of Nova Scotia459KShares$486,7450.0% of portfolio
-
Bank Of Montreal Toronto, A6422KShares$447,4010.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny399KShares$422,7850.0% of portfolio
-
Bank Of America Corp Charlotte, NC386KShares$408,6410.0% of portfolio
-
Black Rock Inc. New York, NY300KShares$317,6850.0% of portfolio
Latest Institutional Activity in ANTX
Top Purchases
Top Sells
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Transactions at ANTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
Gilbert Lynn Marks |
BUY
Grant, award, or other acquisition
|
Direct |
11,875
+18.2%
|
-
|
|
Jul 10
2025
|
Kabeer Aziz |
BUY
Grant, award, or other acquisition
|
Direct |
11,875
+27.99%
|
-
|
|
Jul 10
2025
|
Patricia A. Martin |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+27.31%
|
-
|
|
Jun 02
2025
|
Eric Easom Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+3.75%
|
$10,000
$1.07 P/Share
|
|
May 30
2025
|
Braden Michael Leonard |
SELL
Open market or private sale
|
Indirect |
432,000
-5.93%
|
$432,000
$1.02 P/Share
|
|
May 28
2025
|
Braden Michael Leonard |
SELL
Open market or private sale
|
Indirect |
2,300,000
-14.56%
|
$2,300,000
$1.14 P/Share
|
|
May 28
2025
|
Margaret M Fitz Patrick |
BUY
Open market or private purchase
|
Direct |
8,610
+50.0%
|
$8,610
$1.18 P/Share
|
|
Apr 10
2025
|
Patricia A. Martin |
BUY
Grant, award, or other acquisition
|
Direct |
3,065
+32.97%
|
-
|
|
Apr 10
2025
|
Joseph S Zakrzewski |
BUY
Grant, award, or other acquisition
|
Direct |
10,523
+6.74%
|
-
|
|
Apr 10
2025
|
Gilbert Lynn Marks |
BUY
Grant, award, or other acquisition
|
Direct |
9,705
+18.95%
|
-
|
|
Apr 10
2025
|
Kabeer Aziz |
BUY
Grant, award, or other acquisition
|
Direct |
9,705
+34.19%
|
-
|
|
Feb 26
2025
|
Lucy Day Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,500
+37.0%
|
-
|
|
Feb 26
2025
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,250
+38.56%
|
-
|
|
Feb 26
2025
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
145,250
+37.09%
|
-
|
|
Feb 26
2025
|
Joshua M Eizen |
BUY
Grant, award, or other acquisition
|
Direct |
58,500
+25.04%
|
-
|
|
Feb 26
2025
|
Stephen David Prior Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+31.35%
|
-
|
|
Jan 03
2025
|
Sanjay Chanda Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,957
-9.02%
|
$2,957
$1.34 P/Share
|
|
Jan 03
2025
|
Lucy Day Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,957
-8.3%
|
$2,957
$1.34 P/Share
|
|
Jan 03
2025
|
Joshua M Eizen |
SELL
Open market or private sale
|
Direct |
9,663
-7.65%
|
$9,663
$1.34 P/Share
|
|
Jan 03
2025
|
Stephen David Prior Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,029
-5.74%
|
$2,029
$1.34 P/Share
|
Last 12 Months Summary
Buy / Acquisition
901K
Shares
From
14
Insiders
| Grant, award, or other acquisition | 471K shares |
|---|---|
| Open market or private purchase | 431K shares |
Sell / Disposition
2.75M
Shares
From
5
Insiders
| Open market or private sale | 2.75M shares |
|---|